Print Page     Close Window     

SEC Filings

AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document


benefit liability, (iv) income taxes and (v) share-based compensation. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.


Income taxes


As disclosed in Note 14, the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses.


Segment reporting


The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.


The Company is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one reportable segment. Non-current assets are located in and revenue is attributable to the Company’s country of domicile, Switzerland.


Accounting pronouncements – not yet adopted


The following pronouncements from the IASB will become effective for future financial reporting periods and have not yet been adopted by AC Immune.


IFRS 16 Leases provides a new model for lessee accounting in which all leases, other than short-term and low-value leases, will be accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and the subsequent amortization of the right-of-use asset over the lease term. IFRS 16 will be effective for annual periods beginning on or after January 1, 2019 with early adoption permitted. AC Immune has completed its assessment of the impact of this standard on its financial statements and we estimate an increase of approximately CHF 2.2 million for the right-of-use assets and lease liabilities associated with our operating leases upon adoption. The Company will adopt this standard as of the effective date using the Modified Retrospective approach with there being no cumulative effect adjustment to the opening balance of accumulated losses. We believe the adoption of this standard will not have a significant impact on our statements of loss and comprehensive loss, changes in equity, and cash flows.


There are no other standards that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.


Accounting pronouncements – recently adopted


IFRS 15 Revenue from Contracts with Customers


In May 2014, the International Accounting Standards Board (IASB) issued IFRS 15 – Revenue from Contracts with Customers which amends the guidance for accounting for revenues from contracts with customers. This IFRS replaces all current revenue standards in IFRS including IAS 11 – Construction Contracts, IAS 18 – Revenue and various interpretations. The Company adopted this new standard on January 1, 2018, and would have recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of accumulated losses; however, the Company did not deem any adjustments required in the transition to the new standard. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.


IFRS 9 Financial Instruments


IFRS 9 Financial Instruments supersedes IAS 39 Financial Instruments: Recognition and Measurement and was adopted by the Company on January 1, 2018. IFRS 9 covers classification and measurement of financial assets and financial liabilities, impairment of financial assets and hedge accounting. The Company noted no impact to its financial statements upon adoption of this standard.



© AC Immune 2015